ABBOTT PARK, Ill. and BAGSVÆRD, Denmark, Feb. 20, 2019 /PRNewswire/ — Abbott (NYSE: ABT) and Novo Nordisk today announced a non-exclusive partnershi
Source: www.prnewswire.com
Abbott and Novo Nordisk have entered into a non-exclusive partnership to integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system. This partnership will make the management of diabetes easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens. Abbott is a global healthcare leader with a portfolio of life-changing technologies healthcare, with diagnostics, medical devices, nutrition and branded generic medicines. Novo Nordisk has over 95 years of experience in diabetes care, and aims to help people defeat obesity, haemophilia, growth disorders, and other serious chronic diseases.
